• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CeMM, Haplogen make collection of human cell lines available

CeMM, Haplogen make collection of human cell lines available

August 26, 2013
CenterWatch Staff

Haplogen, a biotechnology company developing antiviral therapies, and CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, are making available their large collection of human cell lines that are deficient for single genes, which they have been building over the past three years as part of a public-private partnership. The partnership, through Haplogen, will distribute requested cell lines to the research community.

The collection currently includes cell line clones covering 3,000 different human genes, which represents about one third of all the genes active in these cells. The collection will continue to expand until all the genes have been targeted.

Georg Casari, CEO of Haplogen, said, “We have taken great care to document that the gene products are gone and that those clones have new properties as compared to the parental, unmodified cell line. Our goal is to eventually obtain mutant cell lines for every human gene.”

Although cell lines of human origin have been around for many years, they are all different from each other, making them difficult to control when performing genetic experiments, thereby limiting their use particularly for drug discovery efforts and discovering the function of genes. This new collection circumvents this problem by providing individual gene mutations in an otherwise identical genetic background.

“This collection will fuel research in molecular medicine where the vast majority of human genes remain poorly understood and await functional characterization,” said Prof. Giulio Superti-Furga, director of the CeMM and project initiator. “Obtaining human cells where an individual gene is inactivated so far has been difficult and tedious. With this, we expect to drive countless scientific discoveries in the research community.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing